Researchers studied LA, San Francisco, Chicago, New York and Raleigh-Durham
The rates of community-onset methicillin-resistant Staphylococcus aureus (CO-MRSA) varied dramatically among academic medical centers in California, New York, Illinois and North Carolina, suggesting there is not a uniform change in the "national epidemic" of the "superbug" that has generated extensive public health concern over the past decade, according to a new study.
Dr. Brad Spellberg, LA BioMed infectious disease specialist, says dramatic differences in the incidence and rate of change in the number of MRSA and MSSA infections indicate ongoing, fundamental changes in bacterial ecology.
Credit: LA BioMed
The study, published online ahead of print in the journal Clinical Infectious Diseases, surveyed hospital records of 4,171 cases of MRSA and MRSA-related infections between 2008 and 2011 in five medical centers located in Los Angeles, San Francisco, Chicago, New York City and Raleigh-Durham, NC.
The rates of MRSA acquired in the community declined 57% from 2008-2011 in the Los Angeles medical center. In contrast, CO-MRSA rates tripled at the New York medical center, while the rates remained stable in San Francisco, Chicago and Raleigh-Durham. At the same time, the rates for a MRSA-related infection, methicillin-susceptible S. aureus (MSSA), tended to change in the opposite direction from MRSA rates.
Since MRSA and MSSA rates moved in opposite directions, the authors concluded: "Enhanced infection control efforts are unlikely to account for such variation in community onset infection rates"
"These dramatic differences in the incidence and rate of change in the number of MRSA and MSSA infections indicate ongoing, fundamental changes in bacterial ecology, which need further study to protect public health," said Brad Spellberg, MD, a Los Angeles Biomedical Research Institute (LA BioMed) infectious disease specialist and senior author of the study. "Fully understanding MRSA, MSSA and other antibiotic-resistant infections is essential to finding new approaches to save the lives and protect the health of our patients here and around the world."
First recognized in the early 1960s, MRSA became a major public health concern in the late 1980s because it had become endemic in most U.S. hospitals. In the 1990s, a new wave of the antibiotic-resistant staph infections acquired in the community swept the nation. These were not caused by bacteria that had escaped from the hospital. They were MSSA strains with a novel resistance element. These MSSA strain types, especially the ones with a genetic background known as USA 300, were highly virulent. Driven by the emergence of USA300, the incidence of MRSA infections rose dramatically in the 2000s.
In the mid-1990s, Los Angeles and Chicago were among the first regions in the country to be affected by the emergence of MRSA acquired in the community. The "epidemic" of these community-acquired antibiotic-resistant infections only recently reached New York, leading researchers to conclude that the relatively stable incidence of CO-MRSA in Chicago and the decline in Los Angeles will begin to be seen in East Coast cities in the near future.
"This study also found that more than half the MRSA cases involved the most virulent form of the bacteria, bacterium with the USA300 genetic background. But the incidence varied from 35% at one hospital to 80% at another," said Dr. Spellberg. "All these differences in rates suggest that the epidemiology and other factors of antibiotic resistance vary greatly, requiring further study to fully understand antibiotic-resistant bacteria."
Dr. Spellberg is the author of the book, "Rising Plague," which examined the rise of antibiotic resistant infections and the failure to develop new antibiotics to combat them. The other researchers engaged in the study were: Arnold S. Bayer, Loren G. Miller and Raul Macias-Gil, LA BioMed; Michael Z. David, Robert S. Daum, Alison Baesa, Susan Boyle-Vavra and Julia Sieth, University of Chicago; Henry F. Chambers and Joann Volinski, University of California, San Francisco; Vance G. Fowler, Jr. and Thomas H. Rude, Duke University Medical Center, and Belinda Ostrowsky and Philip Gialanella, Montefiore Medical Center/Albert Einstein College of Medicine in New York.
About LA BioMed
Founded in 1952, LA BioMed is one of the country's leading nonprofit independent biomedical research institutes. It has approximately 100 principal researchers conducting studies into cancer, inherited diseases, infectious diseases, illnesses caused by environmental factors and much more. It also educates young scientists and provides community services, including prenatal counseling and childhood nutrition programs. LA BioMed is academically affiliated with the David Geffen School of Medicine at UCLA and located on the campus of Harbor-UCLA Medical Center. For more information, please visit http://www.LABioMed.org
Laura Mecoy | Eurek Alert!
Speed data for the brain’s navigation system
06.12.2016 | Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE)
Study suggests possible new target for treating and preventing Alzheimer's
02.12.2016 | Oregon Health & Science University
In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.
Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...
Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...
A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.
Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...
In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.
“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...
The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.
The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...
16.11.2016 | Event News
01.11.2016 | Event News
14.10.2016 | Event News
07.12.2016 | Earth Sciences
07.12.2016 | Earth Sciences
07.12.2016 | Materials Sciences